HNRNPU K181 Lactylation Drives Cervical Cancer Growth by Upregulating PHGDH and Reprogramming Serine Metabolism
Advanced Science · 2026-08 · 13 (47)
DOI: 10.1002/advs.202520222 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 27.05.2026. Verfasst von Chang Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Serine, Phosphoglycerate Dehydrogenase, Heterogeneous-Nuclear Ribonucleoproteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Talent Reserve Program of The First Hospital of Jilin University, Graduate Innovation Fund of Jilin University.
Abstract (Originalsprache)
Cervical cancer remains a major global health burden, yet the molecular mechanisms driving its metabolic reprogramming are incompletely understood. Here, we identify heterogeneous nuclear ribonucleoprotein U (HNRNPU) as a novel non‐histone substrate of lysine lactylation that links lactate accumulation to serine metabolism and tumor progression. We demonstrate that lactylation at lysine 181 (K181) stabilizes HNRNPU, enhances its binding to PHGDH mRNA, and maintains the exon 1‐containing PHGDH transcript and mRNA stability, thereby sustaining PHGDH expression and activating the serine biosynthesis pathway. This metabolic rewiring promotes redox homeostasis, nucleotide synthesis, and cervical cancer cell proliferation both in vitro and in vivo. Mechanistically, we reveal a competitive interplay between lactylation and NAA50‐mediated acetylation at K181, establishing a dynamic post‐translational modification switch that fine‐tunes HNRNPU function. Importantly, pharmacological inhibition of HNRNPU K181 lactylation by Pazopanib suppresses PHGDH expression and tumor growth, underscoring its translational potential. Collectively, our findings uncover a lactate‐driven regulatory axis in which HNRNPU K181 lactylation integrates metabolic signaling with post‐transcriptional regulation to promote cervical cancer progression, providing a promising therapeutic avenue for targeting metabolic vulnerabilities in malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, China.
- Department of Urology, The First Hospital of Jilin University, Changchun, China.
Förderung
- National Natural Science Foundation of China
- Talent Reserve Program of The First Hospital of Jilin University
- Graduate Innovation Fund of Jilin University
Zitieren
APA
Zhang, C., Meng, Q., Jiao, H., Liu, H., Wang, X., Zhou, H., & Wang, Y. (2026). HNRNPU K181 Lactylation Drives Cervical Cancer Growth by Upregulating PHGDH and Reprogramming Serine Metabolism. Advanced Science, 13(47). https://doi.org/10.1002/advs.202520222
Vancouver
Zhang C, Meng Q, Jiao H, Liu H, Wang X, Zhou H, et al. HNRNPU K181 Lactylation Drives Cervical Cancer Growth by Upregulating PHGDH and Reprogramming Serine Metabolism. Advanced Science. 2026;13(47). doi:10.1002/advs.202520222
BibTeX
@article{Zhang2026,
author = {Zhang, Chang and Meng, Qingfei and Jiao, Hui and Liu, Huixin and Wang, Xiangchao and Zhou, Honglan and Wang, Yishu},
title = {HNRNPU K181 Lactylation Drives Cervical Cancer Growth by Upregulating PHGDH and Reprogramming Serine Metabolism},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {47},
doi = {10.1002/advs.202520222}
}
EUVIMED